http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
-
Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting
-
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
-
Athira Pharma Inc. (ATHA) Reports Topline Results from Phase 2/3 LIFT-AD Trial of Fosgonimeton
-
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease
-
Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
-
Athira Pharma (ATHA) Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology
-
Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Associati
-
Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
-
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
-
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
-
Athira Pharma to Participate in Upcoming June Conferences
-
Athira Pharma (ATHA) Announces Proposed Settlement of Stockholder Derivative Action
-
Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
-
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
-
Athira Pharma to Participate in Upcoming May Conferences
-
Athira Pharma Inc. (ATHA) Appoints Javier San Martin as Chief Medical Officer
-
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
-
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
-
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
-
Athira Pharma (ATHA) Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton
-
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
-
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
-
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
-
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
-
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
-
Athira Pharma (ATHA) Reports Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton
-
Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
-
Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
-
Athira Pharma to Participate in Sidoti December Small Cap Investor Conference
-
Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND
-
Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton’s Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer’s Disea
-
Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates
-
Athira Pharma to Participate in Jefferies London Healthcare Conference
-
Athira Pharma (ATHA) Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis
-
Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
-
Athira Pharma to Participate in Upcoming October Conferences
-
Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
-
Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates
-
Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer’s
-
Athira Pharma Announces Upcoming Presentations at the Alzheimer’s Association International Conference (AAIC) 2023
-
Athira Pharma to Participate in Upcoming June Conferences
-
Athira Pharma Inc. (ATHA) Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer
-
Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer
-
Athira Pharma Reports First Quarter 2023 Financial Results and Recent Pipeline and Business Updates
-
Athira Pharma to Participate in Upcoming May Investor Conferences
-
Athira Pharma Inc. (ATHA) Presents New Clinical and Preclinical Data
-
Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting
-
Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting
-
Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting
